Highest-materiality recent filing
Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA
Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.
Cryoport shareholders elect directors, approve equity plan amendment at 2026 annual meeting
All six director nominees elected with substantial majority (e.g., Linda Baddour got 38.9M votes for).
Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M
Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).
Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M
FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.
Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M
Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.
Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance
Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.
Cryoport completes CRYOPDP divestiture to DHL for ~$200M in cash; launches strategic partnership
Total cash consideration of ~$200M: $133M purchase price plus repayment of $77.2M in intercompany loans.
Cryoport stockholders elect all director nominees and set say-on-pay frequency at 1 year
All six director nominees elected with votes ranging from 35.2M to 39.5M; broker non-votes 3.8M.
Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%
Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.
Cryoport sells CRYOPDP to DHL for $195M enterprise value, forms strategic partnership
Divests CRYOPDP to DHL for total enterprise value of $195M; ~$138M cash plus repayment of ~$67M intercompany loans.
Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M
FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).
Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%
Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.
Cryoport authorizes $200M repurchase program; repurchases $160M convertible notes at 11.5% discount
Board authorized up to $200M repurchase of common stock and/or convertible notes, effective Aug 1, 2024 through Dec 31, 2027.
Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M
Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.
Cryoport shareholders elect directors and approve equity plan amendment at 2024 annual meeting
All eight director nominees elected; Richard Berman received 20.5M votes for and 24.0M withheld.
Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M
Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.
Cryoport FY 2023 revenue $233.3M (-2% YoY); net loss $99.6M; guides FY 2024 $242-252M
Q4 revenue $57.3M (-5% YoY); FY revenue $233.3M (-2% YoY). Services grew 8% but product fell 14%.
Cryoport appoints Edward Zecchini as SVP CDTO; CEO, CFO, CSO contracts amended through 2027
Edward Zecchini resigned from Board effective Feb 19, 2024, to become Senior VP & Chief Digital & Technology Officer.
Cryoport amends bylaws to comply with SEC universal proxy rules
Bylaw amendments effective Nov 9, 2023, update director nomination procedures.
Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance
Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.
Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M
Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.
Cryoport expects Q2 revenue down 11% YoY; slashes FY2023 guidance to $233M-$243M
Preliminary Q2 revenue $56.5M-$57.5M, down ~11% YoY; weak capital equipment demand.
Cryoport AGM: high withhold votes for three directors; say-on-pay and auditor ratified
Ramkumar Mandalam received 20.8M withhold votes; Robert Hariri 17.9M; Richard Berman 15.9M.
Record Q1 revenue of $62.8M, up 20% YoY; net loss narrows to $0.16/share
Revenue $62.8M, +20% YoY (+23% constant currency); Biopharma/Pharma +19%, Animal Health +30%, Reproductive Medicine +13%.
Cryoport extends CFO Robert Stefanovich's employment agreement to Nov 1, 2026
CFO employment term extended to November 1, 2026 via First Amendment to Employment Agreement dated March 24, 2023.
Cryoport dismisses EY as auditor, appoints Deloitte for FY 2023
Audit Committee approved dismissal of Ernst & Young and appointment of Deloitte & Touche, effective March 9, 2023.
Cryoport reports Q4 2022 revenue $60.4M, full-year record $237.3M; guides FY2023 revenue $270-290M
Full-year 2022 revenue $237.3M, up 7% YoY; commercial therapy revenue up 27% to $16.3M.
Cryoport Q3 revenue up 7% to $60.5M, cuts FY 2022 guidance to $232-$238M on macro headwinds
Q3 revenue $60.5M (+7% YoY); net loss $7.3M ($0.15/share); adj. EBITDA $4.7M vs $6.0M YoY.
Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed
Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).
Eight director nominees elected: Baddour, Berman, Hancock, Hariri, Jagannath, Mandalam, Shelton, Zecchini; all received majority of votes cast.
Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M
Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.
Cryoport enters employment agreement with CSO Sawicki; extends Shelton's contract to 2026
Dr. Mark Sawicki enters 3-year employment agreement as Chief Scientific Officer and CEO of Cryoport Systems, LLC.
Cryoport authorizes $100M share and convertible note repurchase program through Dec 2025
Board authorized up to $100M repurchase of common stock and/or convertible senior notes.
Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment
FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.
Cryoport expects MVE New Prague production resumption Feb 14; $4-5M Q1 revenue impact
Fire on Jan 25 at MVE Biological Solutions' New Prague facility halted production.
Fire occurred January 25, 2022 at MVE Biological Solutions' New Prague, MN manufacturing facility; no injuries reported.
Cryoport issues $402.5M 0.75% convertible notes due 2026, repurchases $100.7M 2025 notes
Issued $402.5M principal of 0.75% Convertible Senior Notes due 2026; includes $52.5M from full exercise of initial purchasers' option.
Cryoport prices $350M 0.75% convertible notes due 2026 and $248.6M equity placement
Upsized $350M aggregate principal of 0.75% convertible notes due Dec 2026; initial purchasers' option for additional $52.5M.
Announces $300M convertible senior notes due 2026; initial purchasers have option for additional $45M.
Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported
Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.
Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA
Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.
On February 10, 2024, Edward Zecchini accepted the offer to join Cryoport, Inc. (the “Company”) as Senior Vice President – Chief Digital & Technology Officer and submitted his resignation from the Board of Directors of the Company both effective February 19, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings